Kite Pharma Inc said on Tuesday it had formed a joint venture with Shanghai Fosun Pharmaceutical (Group) Co Ltd to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront...
Japan’s Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
Japan’s Takeda Pharmaceutical Co (4502.T) flagged its appetite for fresh acquisitions to bolster its drug portfolio after agreeing on Monday to acquire cancer drug maker Ariad Pharmaceuticals (ARIA.O) in a $5.20...
Valeant to sell assets for $2.12 billion to ease debt load
Valeant Pharmaceuticals International (VRX.TO) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than $30 billion in...
ChrysCapital to sell stake in Intas Pharma
Home-grown private equity (PE) firm ChrysCapital has decided to offload its remaining stake in Intas Pharmaceuticals Ltd, a privately held drug maker based in Ahmedabad, and is holding discussions to dilute at least...
Valeant to sell Dendreon unit to China’s Sanpower for $820 million
Canada’s Valeant Pharmaceuticals International Inc (VRX.TO) said its affiliate will sell its Dendreon cancer business to China’s Sanpower Group Co Ltd [SPGCL.UL] for $819.9 million, as the drugmaker...
Japan’s Takeda to buy US cancer drug maker Ariad in $5.2 billion deal
apan’s Takeda Pharmaceutical Co Ltd said on Monday it would buy cancer drug maker Ariad Pharmaceuticals Inc. in a deal valued at $5.20 billion, to beef up its oncology pipeline. Ariad stock was up 74.7% at $23.98 in pre...
France’s Ipsen to buy Merrimack’s pancreatic cancer drug, assets in $1 billion deal
French drugmaker Ipsen SA (IPN.PA) said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc (MACK.O), including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company...
Aurobindo Pharma buys Generis in a bid to boost margins in Europe
Aurobindo Pharma Ltd wanted an acquisition that could lift the profitability of its European operations; its earnings before interest, taxes, depreciation and amortization (Ebitda) margin was in the mid-single digits...
FIPB approves Sweden-based Recipharm’s Kemwell acquisition
Swedish company Recipharm, a pharmaceutical contract development and manufacturing organisation (CDMO), on 30 December 2016 announced that it has received the Foreign Investment Promotion Board’s (FIPB) approval for its...
U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal
German pharmaceutical company Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition, the U.S. Federal Trade Commission...
Zydus Cadila acquires six brands from Merck India
Ahmedabad-based drug maker Zydus Cadila has acquired six brands from the Indian unit of US pharmaceutical giant MerckBSE 0.83 % for an undisclosed amount. ZydusBSE -1.03 % in a release late on Wednesday said it has...
Cabinet okays sale of India’s first pharma firm
In the second strategic sale approval in over 12 years, the Cabinet today cleared the sale of India’s first pharma company Bengal Chemicals and Pharmaceuticals Ltd as well as Hindustan Antibiotics Ltd after...
